Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as siRNA
ADX-850 · 1 trial · 2 indications
Incidence, relationship and severity of adverse events and serious adverse events
| Arm | Type | Description |
|---|---|---|
| ADX-850 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ADX-850 | DRUG | siRNA duplex oligonucleotide |
| Placebo | DRUG | Saline |
Key Inclusion Criteria: * Body mass index (BMI) between 18 and 35 kg/m2 * Mild to moderate hypertension, mean of \>130 and \<165mmHg * No use of antihypertensive medication for a minimum of 2 weeks * Willing and able to comply with all study requirements * Willing to take irbesartan as concomitant ...
Top 12 of 20 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Kardigan, Inc. | KARD | 1 | PHASE2 | Tonlamarsen |
| Retension Pharmaceuticals. Inc. | RTSN | 1 | PHASE2 | RTN-001 |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| ADARx Pharmaceuticals, Inc. | ADRX | 1 | PHASE1 | ADX-850 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |